Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Abigail Xie"'
Autor:
Kevin H. Lin, Justine C. Rutter, Abigail Xie, Shane T. Killarney, Camille Vaganay, Chaima Benaksas, Frank Ling, Gaetano Sodaro, Paul-Arthur Meslin, Christopher F. Bassil, Nina Fenouille, Jacob Hoj, Rachel Washart, Hazel X. Ang, Christian Cerda-Smith, Paul Chaintreuil, Arnaud Jacquel, Patrick Auberger, Antoine Forget, Raphael Itzykson, Min Lu, Jiaxing Lin, Mariaelena Pierobon, Zhecheng Sheng, Xinghai Li, Ashutosh Chilkoti, Kouros Owzar, David A. Rizzieri, Timothy S. Pardee, Lina Benajiba, Emanuel Petricoin, Alexandre Puissant, Kris C. Wood
Publikováno v:
Nature Cancer. 3:837-851
Selinexor is a first-in-class inhibitor of the nuclear exportin XPO1 that was recently approved by the US Food and Drug Administration for the treatment of multiple myeloma and diffuse large B-cell lymphoma. In relapsed/refractory acute myeloid leuke
Autor:
James D. Thomas, Sydney X. Lu, Emma De Neef, Erich Sabio, Benoit Rousseau, Mathieu Gigoux, David A. Knorr, Benjamin Greenbaum, Yuval Elhanati, Simon J. Hogg, Andrew Chow, Arnab Ghosh, Abigail Xie, Dmitriy Zamarin, Daniel Cui, Caroline Erickson, Michael Singer, Hana Cho, Eric Wang, Bin Lu, Benjamin H. Durham, Harshal Shah, Diego Chowell, Austin M. Gabel, Yudao Shen, Jing Liu, Jian Jin, Matthew C. Rhodes, Richard E. Taylor, Henrik Molina, Jedd D. Wolchok, Taha Merghoub, Luis A. Diaz Jr, Omar Abdel-Wahab, Robert K. Bradley
Publikováno v:
Cancer Research. 83:5742-5742
Immune checkpoint blockade therapy has revolutionized cancer care, including the treatment of advanced metastatic disease. However, most patients derive little or no clinical benefit from these therapies and many cancer types are notoriously non-resp
Autor:
Abigail Xie, Yeong-ran Ahn, Lorin Crawford, Peter S. Winter, Bryann Pardieu, Justine C. Rutter, Kevin H. Lin, Raiyan T. Sobhan, Antoine Forget, Katherine R. Singleton, Jason W. Locasale, Alexandre Puissant, Grace R. Anderson, Raphael Itzykson, Kris C. Wood, Amy E. Decker, Ziwei Dai, Reinaldo Dal Bello, Emily T. Winn
Publikováno v:
Nature Genetics
Nat Genet
Nat Genet
Local adaptation directs populations towards environment-specific fitness maxima through acquisition of positively selected traits. However, rapid environmental changes can identify hidden fitness trade-offs that turn adaptation into maladaptation, r
Autor:
Eric Wang, Mathieu Gigoux, Sydney X. Lu, Benjamin H. Durham, Luis A. Diaz, Harshal Shah, Erich Sabio, Abigail Xie, Henrik Molina, Arnab Ghosh, Matthew C. Rhodes, Caroline Erickson, Jian Jin, Austin M. Gabel, Jedd D. Wolchok, Dmitriy Zamarin, Daniel Cui, Diego Chowell, Michael E Singer, Benjamin D. Greenbaum, Simon J. Hogg, Richard E. Taylor, James D. Thomas, Omar Abdel-Wahab, Taha Merghoub, Yudao Shen, Andrew Chow, Jing Liu, Hana Cho, David A. Knorr, Yuval Elhanati, Bin Lu, Emma De Neef, Benoit Rousseau, Robert K. Bradley
Publikováno v:
Cell. 184(15)
Summary Although mutations in DNA are the best-studied source of neoantigens that determine response to immune checkpoint blockade, alterations in RNA splicing within cancer cells could similarly result in neoepitope production. However, the endogeno
Autor:
Timothy R. Koves, Abigail Xie, Justine C. Rutter, Timothy S. Pardee, Deborah M. Muoio, David A. Rizzieri, Ryan S. Soderquist, Yeong-ran Ahn, Julia M. Lloyd-Cowden, Jatinder K. Lamba, Amanda G. Nichols, Kris C. Wood, Chad M. McCall, Kevin H. Lin, Nancie J. MacIver
Publikováno v:
Cell Metab
Crosstalk between metabolic and survival pathways is critical for cellular homeostasis, but the connectivity between these processes remains poorly defined. We used loss-of-function CRISPR/Cas9 knockout screening to identify metabolic genes capable o
Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia
Autor:
Cullen Roth, Abigail Xie, Peter S. Winter, Kris C. Wood, Kevin H. Lin, Colin A. Martz, Jennifer P. Tingley, Grace R. Anderson, Elizabeth M. Stein
Publikováno v:
Scientific Reports
ABT-199, a potent and selective small-molecule antagonist of BCL-2, is being clinically vetted as pharmacotherapy for the treatment of acute myeloid leukemia (AML). However, given that prolonged monotherapy tends to beget resistance, we sought to inv